AstraZeneca Buys Boston-Based Startup In Fresh AI Push For Cancer Pipeline
Synopsis
Modella said that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio.
Pharmaceutical giant AstraZeneca (AZN) has purchased Boston-based biomedical AI company Modella AI for an undisclosed sum, according to a statement from the startup on Tuesday.
Modella said that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio.
The company added that the acquisition will embed Modella AI’s multi-modal foundation models and AI agents into AstraZeneca’s oncology research and development environment.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.